证券代码：000525 证券简称：ST 红太阳 公告编号：2023-067 南京红太阳股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 1 二、关于公司实施风险警示期间所采取的措施 特别提示： 南京红太阳股份有限公司（以下简称"公司"）存在被控股股东南京第一农药 集团有限公司（以下简称"南一农集团"）及其关联方非经营性占用公司资金的情 形尚未解决，2022 年度被中兴财光华会计师事务所（特殊普通合伙）出具了否 定意见的内部控制审计报告。鉴此，根据深圳证券交易所《股票上市规则》的相 关规定，公司股票交易于 2023 年 5 月 4 日开市起继续被实施"其他风险警示"。 具体情况详见公司于 2023 年 4 月 29 日披露的《关于公司股票交易继续被实施其 他风险警示暨申请撤销部分其他风险警示情形的公告》（公告编号：2023-029）。 截至目前，公司股票被实施其他风险警示的相关事项暂未消除。 一、公司被实施其他风险警示相关事项的进展情况 在前次进展公告中，公司披露了截至 2023 年 8 月 6 日， ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥1,602,492,213.32, a decrease of 53.90% compared to the same period last year [26]. - Net profit attributable to shareholders was ¥18,021,658.98, down 97.08% year-on-year [26]. - The net cash flow from operating activities was ¥216,383,505.18, reflecting a decline of 51.17% compared to the previous year [26]. - The total assets at the end of the reporting period were ¥10,058,079,466.73, a decrease of 2.17% from the end of the previous year [26]. - The company's weighted average return on equity dropped to 1.41%, down 70.14% from 71.55% in the previous year [26]. - The company's revenue for the reporting period was ¥1,602,492,213.32, a decrease of 53.90% compared to ¥3,476,468,530.27 in the same period last year, primarily due to a decline in sales volume and prices [61]. - Operating costs decreased by 44.65% to ¥1,146,337,907.64 from ¥2,071,048,482.63, mainly due to lower sales volume [61]. - Research and development investment fell by 42.90% to ¥80,142,922.57 from ¥140,345,918.25, reflecting reduced R&D spending during the reporting period [61]. - The company achieved a significant reduction in CO2 emissions and energy consumption per unit of output through its green low-carbon enhancement plan, contributing to a substantial decrease in waste emissions [50]. Market Conditions - The pesticide industry faced challenges with a 17.5% decline in sales volume and a 27.34% drop in sales revenue from January to May 2023 [35]. - The global pesticide market sales in 2022 were $78.715 billion, with a projected decline in 2023 due to falling prices [35]. - The top 100 pesticide companies in China achieved a total sales revenue of ¥327.576 billion, an increase of 28.76% year-on-year [36]. - Despite adverse global market conditions, the company has adjusted its market strategy, focusing on expanding into Australia and Southeast Asia while leveraging new product chains to drive sales growth [45]. Corporate Governance and Compliance - The company is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, with a potential administrative penalty pending [7]. - The company has not provided any forward-looking statements or performance guidance in the available documents [5]. - The company has not engaged in any derivative investments or significant asset sales during the reporting period [73][75]. - The company has received a warning and a fine of CNY 2.5 million from the China Securities Regulatory Commission for information disclosure violations [131]. - The company is committed to complying with regulatory requirements and improving its governance structure to prevent future issues [135]. Environmental Management - The company reported a total wastewater discharge of 9 tons per year, with COD at 7 tons and ammonia nitrogen at 0.79 tons [94]. - The company achieved a VOCs emission level of 3.52 mg/m³, complying with the atmospheric pollutant discharge standard [94]. - The company has implemented continuous monitoring of wastewater and gas emissions to ensure compliance with environmental standards [95]. - The company is focusing on enhancing its wastewater treatment capabilities to reduce environmental impact [95]. - The company has implemented new VOCs absorption devices in Anhui to reduce VOCs emissions and enhance dynamic management of equipment, leading to a significant decrease in emissions [115]. Restructuring and Financial Stability - The company is undergoing judicial restructuring to resolve its debt crisis, with a focus on sustainable high-quality development and collaboration with government and stakeholders [48]. - The company is actively monitoring the restructuring progress of its controlling shareholder to ensure financial stability [82]. - The company has initiated a pre-restructuring process with Hubei Tongfu Investment Management as the strategic investor [82]. - The financial difficulties faced by Nanyi Agricultural Group have led to a crisis affecting its affiliates, resulting in loan cuts and withdrawals by banks [127]. - The company is committed to maintaining the interests of its shareholders and investors by ensuring the return of occupied funds [127]. Legal Challenges - The company is involved in significant litigation matters, including a financial loan contract dispute with Huishang Bank, with an amount involved of 88.54 million yuan [139]. - The company is currently involved in multiple financial disputes, with amounts claimed including 1,480.09 million and 1,541.46 million in various cases [146]. - The company has entered into execution procedures for several financial disputes, indicating ongoing legal challenges [146]. - The company is actively managing its legal disputes to mitigate financial risks and ensure compliance with court decisions [140]. Shareholder Information - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., holds 31.50% of the shares, totaling 182,924,731 shares [178]. - The total number of ordinary shareholders at the end of the reporting period is 26,228 [178]. - The company has not implemented any share buyback or reduction plans during the reporting period [176]. - There are no changes in the number of shares held by major shareholders during the reporting period [178]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters [1]. - The company is exploring potential mergers and acquisitions to enhance its market position, but further details are pending [147]. - The company has set ambitious performance guidance for the upcoming quarters, anticipating continued growth in revenue and profitability [143].

一、审议并通过了《公司 2023 年半年度报告及摘要》。 公司监事会关于 2023 年半年度报告的书面审核意见： 证券代码：000525 证券简称：ST 红太阳 公告编号：2023－065 南京红太阳股份有限公司 第九届监事会第七次会议决议公告 监事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 南京红太阳股份有限公司（以下简称"公司"）第九届监事会第七 次会议于 2023 年 8 月 29 日以通讯方式召开。本次会议通知于 2023 年 8 月 19 日以书面、邮件或通讯等方式发出。本次会议应参加表决 监事 5 名，实际参加表决监事 5 名。会议的召集和召开符合《公司法》 和《公司章程》等有关规定。会议审议并通过了以下议案： 根据《证券法》的要求，公司监事会在对公司 2023 年半年度报 告进行审核后，发表如下书面审核意见： 2 1 特此公告。 南京红太阳股份有限公司 监 事 会 2023 年 8 月 29 日 公司 2023 年半年度报告的编制和审议程序符合法律法规和《公 司章程》的有关规定；公司 2023 年半年度报告的内容和格式符合中 国证监会和深圳证券交易所的相关规 ...

报告期内，控股股东南一农集团及其关联方对公司尚存在历史年 度形成的非经营性资金占用情形，截至本意见函出具日，前述非经营 性资金占用情形尚未解决；报告期内，因银行退回控股股东南一农集 团前期偿还的部分资金，导致报告期内非经营性资金占用金额在报告 期初余额上增加20.58万元，公司已于《关于公司股票被实施其他风 险警示相关事项的进展公告》（公告编号：2023-032）中予以补充披 露说明。 南京红太阳股份有限公司 独立董事关于第九届董事会第八次会议相关事项的意见函 根据《公司法》、《上市公司独立董事规则》、《深圳证券交易 所股票上市规则》、《深圳证券交易所上市公司自律监管指引第1号 ——主板上市公司规范运作》等法律法规及《公司章程》和《公司独 立董事工作制度》的有关规定，作为南京红太阳股份有限公司（以下 简称"公司"）的独立董事，我们对公司第九届董事会第八次会议审议 的有关议案及相关事项进行了认真审阅，基于独立、客观判断的原则， 发表独立意见如下： 一、关于2023年半年度公司控股股东及其他关联方资金占用、对 外担保情况的专项说明和独立意见 根据《上市公司监管指引第8号——上市公司资金往来、对外担 保的监管要求》 ...

编制单位：南京红太阳股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 | 年半年度占用累计 | 2023 | 年半年度占用 | 2023 | 年半年度偿 | 2023 | 年半年度期 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 占用资金余额 | | 发生金额（不含利息） | | 资金的利息（如有） | | 还累计发生金额 | | 末占用资金余额 | 原因 | | | | 南京第一农药集团有限公司 | 控股股东 | 其他应收款 | 158,486.07 | | 20.58 | | | - | | - | 158,506.65 | 往来款 | 非经营性占用 | | | 南京第一农药集团有限公司 | 控股股东 | 其他应收款 | 1,802.80 | | | - | | - | | - | 1,802.80 | ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2023－064 公司董事关于 2023 年半年度报告的书面确认意见： 根据《证券法》的要求，本人作为公司的董事，保证公司 2023 年半年度报告内容真实、准确、完整，不存在任何虚假记载、误导性 陈述或者重大遗漏。 南京红太阳股份有限公司 第九届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 南京红太阳股份有限公司（以下简称"公司"）第九届董事会第八 次会议于 2023 年 8 月 29 日以通讯方式召开。本次会议通知于 2023 年 8 月 19 日以书面、邮件或通讯等方式发出。本次会议应参加表决 董事 9 名，实际参加表决董事 9 名。本次董事会会议材料同时提交公 司监事及高级管理人员审阅。会议的召集和召开符合《公司法》和《公 司章程》等有关规定。会议审议并通过了以下议案： 一、审议并通过了《公司 2023 年半年度报告及摘要》。 董 事 会 2023 年 8 月 29 日 具体内容详见同日公司在巨潮资讯网披露的《公司 2023 年半年 度报告》和《公司 2023 年半年度 ...

证券代码：000525 证券简称：ST 红太阳 公告编号：2023-062 南京红太阳股份有限公司 关于签署《关于参与南京红太阳股份重整投资之意向协议书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、2023 年 8 月 17 日，南京红太阳股份有限公司（以下简称"公司"）与湖北 同富创业投资管理有限公司（以下简称"湖北同富投资"）、预重整管理人签署《关 于参与南京红太阳股份重整投资之意向协议书》（以下简称"《重整投资意向协议》" 或"本协议"）。 2、本次签署的《关于参与南京红太阳股份重整投资之意向协议书》仅为意向 协议，本次重整过程中，各方将根据实际需要签署相关正式协议，具体投资方案 以经湖北同富投资主管国有资产监督管理机构审批通过、南京市中级人民法院裁 定批准的重整计划及各方签署的正式投资协议为准。 3、截至本公告日，公司正在进行预重整，预重整为法院正式受理重整前的程 序，法院最终能否裁定公司进入重整程序尚存在不确定性，重整是否成功也存在 不确定性。敬请广大投资者注意投资风险。 2022 年 9 月 16 日，公司收到南京市中级 ...

Market Overview - The global pesticide market faced significant challenges in the first half of 2023 due to adverse factors such as climate anomalies in North and South America, the escalation of the Russia-Ukraine conflict, and the impact of U.S. interest rate hikes, leading to a substantial decline in market demand compared to the previous year [2] - The prices of glyphosate and glufosinate have dropped significantly, causing a decrease in the overall pesticide market prices and a sluggish transaction volume [2] Product Performance - Despite being banned in some countries, paraquat is still widely used in regions like the U.S., South America, Indonesia, and Africa due to its unique properties as a herbicide [2] - The price of paraquat has stabilized and rebounded recently after a decline influenced by the drop in glyphosate prices [2] New Product Development - The company is actively promoting new products such as dichlorophenoxyacetic acid and chlorantraniliprole, aiming to create new growth [2][3] - The L-glufosinate product has a higher activity level, being over twice as effective as traditional glufosinate, and can reduce application rates by 50%, aligning with national pesticide reduction policies [3] Cost Advantages - The company has developed a cost-effective production process for chlorantraniliprole, utilizing its proprietary intermediate, which results in lower costs and energy savings [3] - The annual production capacity of chlorantraniliprole is set at 2,000 tons, with successful production already established [3] Strategic Response - The company has implemented strategies to adapt to the challenging market conditions, focusing on core business, optimizing product structure, and enhancing operational efficiency [3] - The ongoing pre-restructuring process aims to resolve debt and historical issues, optimizing the company's financial structure and enhancing sustainable development [3]

Financial Performance - The company reported a significant decline in revenue, with total revenue for 2022 amounting to RMB 1.2 billion, a decrease of 15% compared to the previous year[19]. - The net loss for the year was RMB 300 million, representing a loss margin of 25%[19]. - The company's operating revenue for 2022 was ¥6,439,912,658.86, representing a 37.51% increase compared to ¥4,683,382,031.58 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥732,297,405.94, a significant turnaround from a loss of ¥3,744,122,363.59 in 2021, marking a 119.56% improvement[24]. - The net cash flow from operating activities for 2022 was ¥1,142,420,374.26, up 227.68% from ¥348,634,781.59 in 2021[24]. - The basic earnings per share for 2022 was ¥1.2609, a recovery from a loss of ¥6.4468 per share in 2021[24]. - The total assets at the end of 2022 were ¥10,280,802,563.89, a 5.90% increase from ¥9,707,619,065.78 at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were ¥1,271,285,338.83, up 129.50% from ¥553,945,905.99 at the end of 2021[24]. - The company reported a weighted average return on equity of 43.47% for 2022, recovering from -174.73% in 2021[24]. - The gross margin improved to 35%, up from 30% in the previous year, due to cost optimization strategies[59]. Research and Development - Research and development expenses increased by 10% year-on-year, totaling RMB 120 million, reflecting the company's commitment to innovation[19]. - The company is committed to increasing investment in new product and technology development to accelerate product upgrades[43]. - The company holds numerous patents, including 15 invention patents and several utility model patents, enhancing its R&D capabilities and competitive edge in the market[46]. - The company has established a comprehensive technological innovation system for the green pesticide industry, with 4 national-level R&D platforms and 8 provincial-level R&D platforms[66]. - R&D investment amounted to ¥285,370,357.43 in 2022, representing a significant increase of 69.96% compared to ¥167,903,109.85 in 2021, with R&D investment as a percentage of operating revenue at 4.43%[92]. - R&D personnel increased to 658 in 2022, a growth of 2.02% from 645 in 2021, with the proportion of R&D personnel rising to 22.30%[92]. Market Expansion and Strategy - The company plans to focus on expanding its product line, particularly in the pesticide sector, aiming for a 20% increase in market share by 2025[19]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[19]. - The company is focusing on expanding its green pesticide product lines and enhancing its supply chain through strategies like "extending, strengthening, and supplementing" the chain[42]. - The company plans to stabilize revenue growth by actively organizing production and exploring new markets[43]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[59]. - The company plans to enter the European market, with initial sales targets set at 100 million RMB in the first year[61]. Operational Efficiency - The company is implementing new strategies to improve operational efficiency, targeting a 10% reduction in operational costs by the end of 2023[19]. - The company aims to reduce operational costs by 10% through improved supply chain management initiatives[59]. - The company has achieved significant milestones in its judicial restructuring, enhancing asset strength and addressing historical issues, which will benefit investors and local governments[117]. - The company is transitioning to become the world's first "digital green biochemical pesticide" high-tech company, with a focus on integrating digital and biochemical technologies[118]. Environmental Compliance - The company is committed to environmental compliance, holding various permits including pollution discharge licenses valid until 2027[53]. - The company has implemented continuous discharge monitoring systems across its facilities to ensure compliance with environmental standards[188]. - The company has invested CNY 128 million to upgrade its wastewater treatment plant, increasing its capacity to 10,000 tons per day, meeting the highest national water pollutant discharge standards[191]. - The company has established a three-level environmental risk accident water pollution prevention system to ensure wastewater is collected and treated during emergency situations[198]. - The company is actively monitoring and managing its emissions to align with the latest environmental regulations and standards[189]. Governance and Management - The company has a strong emphasis on research and development, with key personnel in technical roles to support product innovation[146][147]. - The governance structure includes a board of directors with 9 members, including 3 independent directors, ensuring effective decision-making and risk management[133]. - The company has strengthened its internal control system, improving management levels significantly, although issues related to non-operating fund occupation remain unresolved[134]. - The company has established an independent financial department and accounting system, ensuring independent financial decision-making, with no shared bank accounts with the controlling shareholder[136]. - The company has emphasized the importance of independent directors in its governance structure, with the election of Wu Xuemin and Yan Zhen as independent directors[145]. Challenges and Risks - The company is under investigation by the China Securities Regulatory Commission for information disclosure violations, which may impact future operations[5]. - The company faces multiple risks, including market, climate, exchange rate, and safety/environmental risks, and has outlined strategies to mitigate these challenges[122][124]. - The company's stock has been under special risk warning since May 6, 2021, due to non-operating fund occupation by controlling shareholders and related parties, with the stock name changed to "ST Hongtai"[125]. - The company has not eliminated the non-operating fund occupation by controlling shareholders and related parties, and is urging repayment[182].